Johnson and Johnson (JNJ) Actualités

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation...

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX®...

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024 PR...

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

BOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inovalon, a leading provider of cloud-based software solutions...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully...

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque...

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress PR...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities